Compare Old Dominion Freight Line Inc (ODFL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs TG Therapeutics Inc — how do they compare? Old Dominion Freight Line Inc trades at $182.28 (market cap $37.68B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Old Dominion Freight Line Inc is far larger — about 4.6× TG Therapeutics Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and TG Therapeutics Inc for 16 Days on average.
| ODFL | TGTX | |
|---|---|---|
Market Cap | $37.68B | $8.16B |
Volume | 1,550,104 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $248.73 | $59.06 |
52-Week Low | $126.29 | $26.94 |
Typical Hold Time | 76 Days | 16 Days |
Enterprise Value | $37.42B | $8.37B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $181.97, up 3.62% today, showing strong momentum after recent earnings beats. The stock faces a bearish technical signal despite positive fundamental metrics including a 19.44% net income margin and consistent earnings outperformance. Recent news highlights a 4.9% general rate increase effective October 5, 2026, aimed at offsetting operating costs while supporting service network investments. Analyst consensus remains mixed with a $230.93 price target suggesting 27% upside potential from current levels.
ODFL presents a compelling growth story with superior profitability metrics and strategic pricing power, though elevated valuation ratios (P/E 34.95) warrant caution. The company's pristine balance sheet with minimal debt and strong cash flow generation supports long-term stability. Key risks include freight market cyclicality and competitive pressures in the trucking industry. Wall Street sentiment leans cautious with 55.56% hold ratings, reflecting valuation concerns despite solid operational performance.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
